Skip to main
INKT
INKT logo

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics Inc demonstrates a promising outlook, supported by early data indicating improvements in pro-inflammatory markers, which could signal potential therapeutic responses in subsequent treatment cycles. The company's innovative CAR-iNKT therapies are positioned uniquely for solid tumor applications due to their capacity for tumor tissue trafficking and enhanced safety profiles, thereby expanding the therapeutic landscape for cancer treatment. Furthermore, the strategic decision to engage in an externally funded investigator-sponsored trial allows MiNK to explore new indications while preserving its own capital, thus bolstering its financial efficiency and strategic focus on advancing its product pipeline.

Bears say

MiNK Therapeutics Inc faces several significant risks that contribute to a negative outlook on its stock, including potential safety concerns emerging from clinical and preclinical programs, and lower-than-expected efficacy outcomes that may not achieve statistical significance. Furthermore, the company could encounter substantial commercial competition from existing and developing treatments, alongside regulatory challenges that may affect its clinical assets. Financially, MiNK is projected to require approximately $55 million in additional financing through 2038, with a cash runway extending only into mid-2025, while reporting an operating loss of $2.5 million and an earnings per share of -$0.62 for the fourth quarter of 2024.

MiNK Therapeutics (INKT) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Buy based on their latest research and market trends.

According to 4 analysts, MiNK Therapeutics (INKT) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.